NVP-BVU972 (also names as BVN972; BVN-972) is a novel c-Met inhibitor with potential anticancer activity.

PF-04217903 mesylate, the methanesulfonate salt of PF-04217903, is a novel, potent, orally bioavailabe, selective, and ATP-competitive small-molecule tyrosine kinase inhibitor of c-Met with IC50 of 4.8 nM in A549 cell line and with anticancer activity, it is susceptible to oncogenic mutations (with no activity to Y1230C mutant).

This product has been discontinued. Tepotinib (formerly EMD 1214063, EMD-1214063; MSC2156119; MSC-2156119; Tepmetko) is a selective c-Met inhibitor with potential antineoplastic activity.

Savolitinib (volitinib, AZD-6094, HMPL-504; Orpathys; HUTCHMED) is a novel, potent, orally bioactive and selective inhibitor of the c-Met receptor kinase with anticancer activity.

Tyrosine kinase inhibitor is novel and potent Tyrosine kinase inhibitor.

Crizotinib (formerly known as PF-02341066; trade name: Xalkori) is a potent, orally bioavailable small molecule inhibitor of c-Met and ALK with potential anticancer activity.

OMO-1 (formerly known as JNJ-38877618) is a novel, potent, highly selective and orally bioavailable Met kinase inhibitor with nM binding affinity (Kd=1.4 nM) and enzyme inhibitory activity against wt and M1268T mutant MET (IC50 2 and 3 nM ).

Bozitinib (Vebreltinib; formerly APL-101/PLB-1001, CBT-101) is a novel, an ATP-competitive, and highly selective c-MET kinase inhibitor with blood-brain barrier permeability.

RXDX-106 (also known as CEP-40783) is an orally bioavailable, nanomolar potent and highly kinase-selective Type II inhibitor of AXL and c-Met with IC50 values of 7 nM and 12 nM, respectively.

AMG 208 (AMG-208) is a novel, highly potent and selective triazolopyridazine-based small molecule inhibitor of c-Met with potential antineoplastic activity.